Olympus (7733) Q1 2025 earnings summary

Executive summary

• Revenue grew 15% year-over-year to ¥234.8 billion, driven by strong North America sales, yen depreciation, and growth in both Endoscopic and Therapeutic Solutions segments.

• Adjusted operating profit rose 32% to ¥37.2 billion, with margin up 2.1 points to 15.9%.

• North America saw 32% revenue growth, with all focus areas performing well; emerging markets grew over 20%.

• The Orthopedic Business was classified as a discontinued operation and its transfer was completed in July 2024.

• Ongoing Elevate remediation and quality transformation program progressing well, with continued compliance to FDA commitments and one-off expenses.

Financial highlights

• Gross profit increased 15% to ¥156.2 billion (66.5% of revenue); gross margin improved as cost-to-sales ratio decreased by 0.4 points to 33.5%.

• Operating profit rose 21% to ¥27.5 billion; adjusted operating profit up 32% to ¥37.2 billion; profit before tax up 33% to ¥26.4 billion.

• Net profit attributable to owners was ¥14.6 billion, down 94% due to discontinued operations and absence of prior-year one-time gains.

• Free cash flow was positive at ¥8.1 billion; adjusted free cash flow (excluding extraordinary factors) was ¥14.8 billion.

• Cash and cash equivalents at quarter-end were ¥276.0 billion, down ¥65.0 billion from March 2024 due to debt repayment and dividends.

Outlook and guidance

• FY2025 guidance remains unchanged: revenue forecast ¥1,009.0 billion, adjusted operating profit ¥197.5 billion, EPS ¥106.

• First quarter results progressing in line with full-year guidance.

• Cost controls will be tightened if top-line performance weakens, with a commitment to deliver a 19.6% bottom line.

• Growth in China expected to be challenging; high single-digit growth now seen as difficult.

• Dividend forecast raised to ¥20 per share (year-end).